A research team has developed a technology that distinguishes lung cancer gene mutations solely by measuring the "stiffness" of exosomes—tiny particles released from cancer cells in the ...

Medically reviewed by Marla Anderson, MD About 40% of people with non-small cell lung cancer (NSCLC)—a type of cancer that begins in the tissues of your lungs—have metastatic disease at the time of ...

Non-small cell lung cancer (NSCLC) accounts for over 80% of lung cancer cases and is often diagnosed at advanced stages, ...

There is a great need to streamline the process from the tissue sample to the diagnostic lab, whether it's genomic or ...

New research identifies NF-kappa-B-activating protein-like (NKAPL) as a potent tumor suppressor in non-small cell lung cancer ...

In December 2024, the FDA approved Ensacove as a first-line treatment for non-small-cell lung cancer (NSCLC) in certain adults. NSCLC is the most common type of lung cancer.

Imdelltra received accelerated approval from the U.S. Food and Drug Administration in May 2024 for patients with extensive-stage small cell lung cancer with disease progression on or after ...

The drug is being developed for the treatment of small cell lung cancer and neuroendocrine carcinoma, including neuroendocrine prostate cancer. The multi-center, first-in-human, open-label, phase 2/3 ...

Amgen has detailed a positive phase 3 readout for its T-cell engager Imdelltra in previously treated small cell lung cancer (SCLC). The DLL3xCD3 bispecific has shown that it can help patients live ...

They looked at blood samples from 41 patients with lung cancer (mostly non-small cell) treated with curative intent for stage I to III disease (mostly stage III). Median follow-up was 35 months.